Pembrolizumab/Quavonlimab

帕博利珠单抗/齐沃利单抗

Report date: 2026/05/07 20:00:36

Base Information

Drug NamePembrolizumab/Quavonlimab
Drug Alias NameMK-1308A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionProgrammed cell death protein 1 blockersCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaColorectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[41] 
CombinationsYes PembrolizumabQuavonlimab
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMerck Sharp & Dohme CorpMsd Ireland (Carlow)MSD R&D（China）Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMsd Ireland (Carlow)Merck Sharp & Dohme CorpMerck Sharp & Dohme LLC +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaColorectal Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A